PACE-CME

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

ARNI seems to give CV benefit not only in HFrEF but up to EF of about
RestartResume
3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia
  • Overview

    AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

  • Educational information

    This video was recorded at the AHA in Philadelphia, USA, on November 17, 2019.

  • Faculty

    Scott David Solomon is Director Noninvasive Cardiology, Cardiovascular Medicine, Brigham and Women's Hospital and Professor at Harvard Medical School, Boston, MA, USA.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    READ OUR SUMMARY OF THE RESULTS OF THIS TRIAL

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free